公开(公告)号：US20230025836A1

公开(公告)日：2023-01-26

申请号：US17756266

申请日：2020-11-20

Applicant: Samjin Pharmaceutical Co., Ltd. ,  AptaBio Therapeutics Inc.

Inventor： Min-hyo Ki ,  Jin-cheul Kim ,  Mee-Hwa Choi ,  Dong-Ha Lee ,  Sung Hwan Moon ,  Soo Jin Lee

IPC: A61K31/4155 ,  A61K9/00 ,  A61P27/02

Abstract: The present invention relates to an ophthalmic preparation containing an active ingredient selected from 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol compound or a pharmaceutically acceptable salt thereof. The eye drop according to the present invention is excellent in stability and safety and shows an excellent effect on prevention or treatment of eye diseases in such a way that an active ingredient thereof reaches a posterior segment of an eyeball simply through instillation rather than a direct injection into an eyeball.

公开(公告)号：US20220218685A1

公开(公告)日：2022-07-14

申请号：US17614705

申请日：2020-05-29

Applicant: Samjin Pharmaceutical Co., Ltd. ,  AptaBio Therapeutics Inc.

Inventor： Min-hyo Ki ,  Kyung-wan Nam ,  Jin-cheul Kim ,  Kyung-jin Ahn ,  Sung Hwan Moon ,  Soo Jin Lee

IPC: A61K31/4439 ,  A61K47/34 ,  A61K9/00 ,  A61P27/02

Abstract: The present invention relates to a composition for treating eye diseases, wherein the composition comprises a pyrazole-based compound, which is a pharmacologically active substance, and a biodegradable polymer, so that a drug effectively reaches a posterior segment of an eyeball, while prolonging an action time of the drug administered into the eyeball.

公开(公告)号：US11174240B2

公开(公告)日：2021-11-16

申请号：US16605380

申请日：2018-04-20

Applicant: Aptabio Therapeutics Inc.

Inventor： Sung Hwan Moon ,  Soo Jin Lee ,  Sung Chan Lee

IPC: C07D401/04

Abstract: The present invention relates to a novel crystalline 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride, a method for preparing the compound, and a pharmaceutical composition containing the compound as an active ingredient.

公开(公告)号：US20210122726A1

公开(公告)日：2021-04-29

申请号：US16605380

申请日：2018-04-20

Applicant: Aptabio Therapeutics Inc.

Inventor： Sung Hwan Moon ,  Soo Jin Lee ,  Sung Chan Lee

IPC: C07D401/04

Abstract: The present invention relates to a novel crystalline 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride, a method for preparing the compound, and a pharmaceutical composition containing the compound as an active ingredient.

公开(公告)号：US11999718B2

公开(公告)日：2024-06-04

申请号：US18150955

申请日：2023-01-06

Applicant: Aptabio Therapeutics Inc.

Inventor： Soo Jin Lee ,  Sung Hwan Moon ,  Sooho Ban ,  Eunsil Lee ,  Eun Jung Shin ,  Yoo-Kyung Goh

IPC: C07D401/14 ,  A61P1/16 ,  A61P11/00 ,  A61P35/00 ,  A61P39/06 ,  C07D231/54 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D495/04

CPC classification number: C07D401/14 ,  A61P1/16 ,  A61P11/00 ,  A61P35/00 ,  A61P39/06 ,  C07D231/54 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D495/04

Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.




(In the above, A, B and R, and the like are the same as defined in the description of the invention.)

公开(公告)号：US20230192752A1

公开(公告)日：2023-06-22

申请号：US16609367

申请日：2018-11-30

Applicant: Aptabio Therapeutics Inc. ,  Samjin Pharmaceutical Co., Ltd.

Inventor： Sung Hwan Moon ,  Soo Jin Lee ,  Yu Mi Ji ,  Hee Jong Shin ,  Min Hyo Ki ,  Yong Bin Park ,  Ji Hyun Um

IPC: C07H21/02 ,  A61K9/00 ,  A61K9/08 ,  A61K47/22 ,  A61P35/02

CPC classification number: C07H21/02 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/22 ,  A61P35/02

Abstract: Disclosed is an oligonucleotide-modified nucleic acid containing at least one 1-β-D-arabinofuranosylcytosine as a modified nucleic acid having therapeutic efficacies and guanosine. More particularly, a novel oligonucleotide-modified nucleic acid containing at least one modified nucleic acid (N) having therapeutic efficacies and being rich in guanosine (G) is synthesized and the fact that the novel oligonucleotide-modified nucleic acid has excellent apoptotic activities on blood cancer cells and drug-resistant blood cancer cells is identified. Based on this, provided is a composition for preventing, ameliorating or treating blood cancer, containing the novel oligonucleotide-modified nucleic acid, and the novel oligonucleotide-modified nucleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

公开(公告)号：US10966969B2

公开(公告)日：2021-04-06

申请号：US16481307

申请日：2018-09-14

Applicant: APTABIO THERAPEUTICS INC.

Inventor： Sung Hwan Moon ,  Soo Jin Lee ,  Sung Chan Lee ,  Yun Soo Bae

IPC: A61K31/4439 ,  A61P1/16

Abstract: Disclosed is a pharmaceutical composition for preventing or treating a fatty liver disease containing, as an active ingredient, a pyrazole-based compound or a pharmaceutically acceptable salt thereof. 3-phenyl-4-alkyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol or a pharmaceutically acceptable salt thereof is capable of effectively inhibiting fatty liver, hepatic inflammation and hepatic fibrosis, and is useful for preventing or treating NAFLD, in particular, NASH.